Form 4: Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 6,866 shares of common stock on August 19, 2024, to cover tax withholding obligations related to vesting RSUs.
Summary
- On August 19, 2024, Jonathan Zalevsky, the Chief R&D Officer of Nektar Therapeutics, sold 6,866 shares of the company's common stock.
- The sale was executed to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- The shares were sold at a weighted average price of $1.28, with individual transactions ranging from $1.24 to $1.32.
- Following the transaction, Zalevsky directly owns 250,804 shares of Nektar Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover tax obligations) and does not contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and employees.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder confidence, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of the stock sale transaction. |
| 08/20/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.